MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..
  


Rayos (prednisone) delayed-release tablets

Company: Horizon Pharma
Approval Status: Approved July of 2012
Treatment for: certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions
Areas: Immune System; Musculoskeletal; Respiratory; Rheumatology

| General Information | Clinical Results | Side Effects | Mechanism of Action | Literature References | Additional Information |


General Information

Rayos is an orally active modified-release formulation of prednisone, a corticosteroid. Corticosteroids are primarily used for their potent anti-inflammatory effects in disorders of many organ systems and they modify the body’s immune responses to diverse stimuli.

Rayos is specifically indicated for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation.

Rayos is supplied as a delayed release tablet for oral administration. The dose of Rayos should be individualized according to the severity of the disease and the response of the patient. The initial dosage of Rayos may vary from 5 to 60 mg per day depending on the specific disease. Rayos should be taken daily with food.


Clinical Results

FDA Approval
The FDA approval of Rayos was based in part on one multicenter, double-blind, placebo-controlled, randomized, 12-week trial in patients with rheumatoid arthritis. This trial enrolled 350 adults not currently treated with corticosteroids but had received non-biologic DMARD therapy for at least 6 months and had an incomplete response to DMARD therapy alone. The subjects were randomized to Rayos 5 mg or placebo administered at 10 pm. The primary endpoint was the percentage of subjects with improvement in rheumatoid arthritis at 12 weeks using ACR response criteria (ACR20). In the Rayos arm, 47% of subjects reached ACR20 versus 29% in the placebo arm. In addition, subjects treated with Rayos had a median decrease in the duration of morning stiffness of 55 minutes compared to 33 minutes in the placebo arm.


Side Effects

Adverse events associated with the use of Rayos may include, but are not limited to, the following:

  • fluid retention
  • alteration in glucose tolerance
  • elevation in blood pressure
  • behavioral and mood changes
  • increased appetite
  • weight gain


Mechanism of Action

Rayos is an orally active modified-release formulation of prednisone, a corticosteroid. Corticosteroids are primarily used for their potent anti-inflammatory effects in disorders of many organ systems and they modify the body’s immune responses to diverse stimuli. The pharmacological effects of prednisone which are due to its corticosteroid properties include: promotion of gluconeogenesis; increased deposition of glycogen in the liver; inhibition of the utilization of glucose; anti-insulin activity; increased catabolism of protein; increased lipolysis; stimulation of fat synthesis and storage; increased glomerular filtration rate and resulting increase in urinary excretion of urate (creatinine excretion remains unchanged); and increased calcium excretion.


Literature References

Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008 Jan 19;371(9608):205-14


Additional Information

For additional information regarding Rayos or inflammatory disorders, please visit the Rayosrx web page.




< back to top

Rayos Drug Information

The Rayos drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.





MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2014 All rights reserved.